


PHARMACEUTICAL 2020



Xenetic Biosciences Inc. Rank 227 of 362





PHARMACEUTICAL 2020



Xenetic Biosciences Inc. Rank 227 of 362

The relative strengths and weaknesses of Xenetic Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xenetic Biosciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 241% points. The greatest weakness of Xenetic Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 157% points.

The company's Economic Capital Ratio, given in the ranking table, is -254%, being 48% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	11,090
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,415
Liabilities, Non-Current	0
Other Assets	10,456
Other Compr. Net Income	0
Other Expenses	3,283
Other Liabilities	2,919
Other Net Income	112
Property and Equipment	0.76
Research and Development	4,889
Revenues	17
Selling, General and Administrative Expense	4,731

Output Variable	Value in 1000 USD
Assets	21,547
Liabilities	4,334
Expenses	12,904
Stockholders Equity	17,213
Net Income	-12,775
Comprehensive Net Income	-12,775
Economic Capital Ratio	-254%